

Supplementary Table 1: Overview of patient information

Patient No.	H. pylori (clinical testing)	Histopathological diagnosis ¹	Gender ²	Age ³	acid suppressive therapy ⁴	anti-H.pylori IgG antibodies (enzyme immunounits)	Giemsa/Warthin Starry staining	Histopathological description ⁵
1	-	Chronic gastritis	female	24	none	5.0	-	small number of LYM and PC, single PMN
2	-	Chronic gastritis	female	57	none	3.9	-	single LYM and PC
3	-	Chronic gastritis	male	50	none	10.0	-	slightly increased number of LYM and PC
4	-	Chronic gastritis	female	30	none	5.9	-	slightly increased number of LYM and PC
5	-	Chronic gastritis	female	31	none	5.2	-	slightly increased number of LYM and PC
6	-	Chronic gastritis	male	56	omeprazole 20 mg/d	12.4	-	slightly increased number of LYM and PC
7	-	Chronic gastritis	female	53	none	4.6	-	single LYM and PC
8	-	Chronic gastritis	female	53	pantoprazole 40 mg /d	11.9	-	single LYM and PC
9	-	Chronic gastritis	male	45	pantoprazole 40 mg /d	6.0	-	slightly increased number of LYM and PC
10	-	Intestinal metaplasia	female	56	none	2.8	-	single LYM and PC
11	-	Chronic gastritis	female	57	none	19.6	-	slightly increased LYM and PC
12	-	Intestinal metaplasia	female	58	pantoprazole 40 mg /d	14.0	-	slightly increased number of LYM
13	-	Chronic gastritis	female	45	none	6.8	-	single LYM and PC
14	-	Intestinal metaplasia	male	78	none	20.5	-	single LYM and PC
15	-	Chronic gastritis	female	61	none	8.7	-	small number of LYM and PC
16	-	Chronic gastritis	male	27	pantoprazole 40 mg /d	18.6	-	small number of LYM and PC
17	+	Chronic active gastritis	male	81	none	nd	-	aggregated LYM, ILF, increased subepithelial LYM and PC
18	+	Chronic active gastritis	female	42	none	56.0	+	aggregated LYM, ILF, increased subepithelial LYM and PC
19	+	Chronic active gastritis	female	68	Pantoprazole 80 mg/d	99.2	+	aggregated LYM, ILF, increased subepithelial LYM and PC
20	+	Chronic active gastritis	female	49	none	58.9	+	aggregated LYM, ILF, increased subepithelial LYM and PC
21	+	Intestinal metaplasia	male	70	none	69.2	+	aggregated LYM, ILF, increased subepithelial LYM, PMN and PC
22	+	Atrophic gastritis	male	56	none	109.7	+	aggregated LYM, ILF, increased subepithelial LYM and PC
23	+	Chronic active gastritis	female	55	pantoprazole 40 mg /d	67.3	+	aggregated LYM, ILF, increased subepithelial LYM, PMN and PC
24	+	Chronic active gastritis	male	52	none	92.8	+	aggregated LYM, ILF, increased subepithelial LYM, PMN and PC

¹ The Fisher's exact test (two-tailed, confidence intervals at 95%) was used to compare the proportions of individuals with intestinal metaplasia between the *Helicobacter* positive and the *Helicobacter* negative group returning a p-value >0.9999, deemed not to be significantly different when setting alpha at 0.05.

² The Fisher's exact test (two-tailed, confidence intervals at 95%) was used to compare the gender proportions between the *Helicobacter* positive and the *Helicobacter* negative group returning a p-value of 0.4120, deemed not to be significantly different when setting alpha at 0.05.

³ The unpaired t-test assuming equally variance (two-tailed) and also not assuming equal variance (with Welch's correction) was used to compare ages between the *Helicobacter* positive and the *Helicobacter* negative group returning a p-value of 0.0947, deemed not to be significantly different when setting alpha at 0.05.

⁴ The Fisher's exact test (two-tailed, confidence intervals at 95%) was used to compare the proportions of individuals taking proton pump inhibitors between the *Helicobacter* positive and the *Helicobacter* negative group returning a p-value of 0.6570, deemed not to be significantly different when setting alpha at 0.05.

⁵ PMN, polymorphonuclear leukocytes; LF, lymphocytic follicles; LYM, lymphocytes; PC, plasmacells